A method of treating cognitive or neurodegenerative diseases, including providing an effective amount of formula compound (1) to a patient in need of such treatment,Or salt acceptable for the same agent, plus the effective amount of ab-n3pglu antibody selected from a group of eight liter, primary and secondary antibodies. 1. Claim 1: a method for treating Alzheimer's disease of patients, which is characterized by providing effective amount of formula compound (1) to patients in need of such treatment,Or a salt acceptable for the same drug, plus the effective amount of ab anti-n3pglu antibody, wherein ab anti-n3pglu antibody includes a variable light chain region (LCVR) and a variable heavy chain region (hcvr),wherein such LCVR comprises LCDR1, LCDR2 and LCDR3 and HCVR comprises HCDR1, HCDR2 and HCDR3 which are selected from the group consisting of: a) LCDR1 is SEQ ID. No. 17, LCDR2 is SEQ ID. No. 18, LCDR3 is SEQ ID. No. 19, HCDR1 is SEQ ID. No. 20, HCDR2 is SEQ ID. No. 21, and HCDR3 is SEQ ID. No. 22, b) LCDR1 is SEQ ID. No. 4, LCDR2 is SEQ ID. No. 6, LCDR3 is SEQ ID. No. 7, HCDR1 is SEQ ID. No. 1, HCDR2 is SEQ ID. No. 2, and HCDR3 is SEQ ID. No. 3； and c) LCDR1 is SEQ ID. No. 4, LCDR2 is SEQ ID. No. 5, LCDR3 is SEQ ID. No. 7, HCDR1 is SEQ ID. No. 1, HCDR2 is SEQ ID. No. 2,HCDR3 is SEQ ID No.3 Claim 8: a method according to any claims 1 to 7, characterized by N - [3 - [(4ar, 7a) - 2-amino-6 - (5-fluopirimin-2-il) - 4, 4a, 5, 7-tetrahypirroro [3, 4-d] [1, 3] tiazin-7a-il] - 4-fluoro-fenil] - 5-methoxi-pirazin-2-carboxamida. 11. Claim 12: drug composition, characterized by a formula compound (1),o una sal del mismo farmac uticamente aceptable con uno oms portadores diluyentes o excipientes farmac uticamente aceptables en combinaci n con una composici n farmac utica de un anticuerpo Ab anti-N3pGlu en donde el anticuerpo Ab anti-N3pGlu comprende una regi n variable de cadena ligera wherein such LCVR comprises LCDR1, LCDR2 and LCDR3 and HCVR comprises HCDR1, HCDR2 and H
